Centralized care for ovarian cancer: a study of outcomes
Part of Cancer, Hormones & metabolism, Infections, Lungs & breathing, Women’s health & pregnancy clinical trials.
This study looks at whether having ovarian cancer care coordinated by a special team (Multidisciplinary Tumor Board) leads to better outcomes. It reviews records of patients treated between 2018 and 2023 to understand how centralization affects their health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 99 years old
- You have been diagnosed with epithelial ovarian cancer (confirmed by biopsy or cell sample)
- Your case was reviewed by the cancer care team at the AUSL-IRCCS in Reggio Emilia, Italy
- You received treatment between January 1, 2018, and December 31, 2023
- Your medical records and outcome information are available for review
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how doctors from different specialties work together in tumor board meetings for ovarian and uterine cancers. It aims to understand team interactions to improve how these meetings help guide patient care.
This study looks at how the immune system works in people with epithelial ovarian cancer. It aims to understand the immune landscape around the tumor, which could lead to better treatments in the future.
This study looks at immune-related markers in people with ovarian cancer to see if they can help predict prognosis (how the cancer may behave). If you qualify, your doctors may use your immune test results alongside other standard treatments like surgery, chemotherapy, and/or immunotherapy.
This study tests a new maintenance therapy for people with advanced ovarian cancer that has responded well to initial chemotherapy. The goal is to see if it helps keep the cancer from coming back.
This trial studies whether an additional treatment after surgery can help people with early-stage epithelial ovarian cancer live longer and stay well for more time. It is meant for patients who had a detailed staging operation and are able to start treatment within 8 weeks.
This study looks at results from surgery to remove as much advanced ovarian cancer as possible after chemotherapy. Participating hospitals are in Italy and Canada.
Hear when a new Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.